Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA

FSNUF

$54.35

Updated: 22/09/2026, 13:03:39

Market Cap
$30.61B
Sector
Healthcare
Industry
Medical - Care Facilities
Country
DE
Stock valuation chart
One-year closing share-price history for FSNUF
Company Profile

Fresenius SE & Co. KGaA is a diversified healthcare enterprise delivering a broad spectrum of products and services across multiple sectors, including dialysis, hospital operations, and outpatient medical treatment. Its operations are structured into four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care specializes in supporting individuals suffering from chronic kidney disease, supplying essential products like dialyzers, hemodialysis equipment, and associated disposable items, alongside comprehensive dialysis services. Fresenius Kabi focuses on the therapeutic management and care of acutely and chronically ill patients. Its portfolio encompasses a wide range of offerings, including intravenous generic pharmaceuticals for areas like oncology, pain management, anesthesia, infection control, and critical care. It also provides parenteral and enteral nutritional solutions, infusion fluids, blood volume expanders, and biosimilar drugs targeting autoimmune and oncological conditions. Furthermore, the segment supplies medical devices and consumables vital for administering IV medications, infusion therapies, and clinical nutrition, along with transfusion products for blood component collection and various bodily treatments. Fresenius Helios manages a substantial network of healthcare facilities. In Germany, it operates 90 hospitals, around 130 outpatient clinics, and six prevention centers. Its Spanish presence includes 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers. Additionally, this segment extends its services to fertility treatment, operating 33 dedicated clinics and 39 supplementary locations spanning ten countries across three continents. Fresenius Vamed is dedicated to project management and service provision for hospitals and other healthcare infrastructure. Its comprehensive offerings range from project conception, detailed planning, and complete turnkey construction to ongoing maintenance, technical oversight, and operational administration. Originally established in 1912, the company was previously known as Fresenius SE before adopting its current name, Fresenius SE & Co. KGaA, in January 2011. Its global headquarters are situated in Bad Homburg vor der Höhe, Germany.

USD
OTC
CEO: Michael Sen
Employees: 178,394
https://www.fresenius.com
Asset Summaries
Latest generated summaries for FSNUF

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for FSNUF.
Share price
$54.35
Market cap
$30.61B
Exchange
OTC
Currency
USD
CEO
Michael Sen
Employees
178,394
IPO date
14/03/2012
Beta
0.834
Last dividend
$0.00
Day range
$54.35 – $57.00
52-week range
$51.89 – $58.16
1-day performance
0.00%
1-year performance
4.74%
Current drawdown (1Y)
-6.55%
CIK
0000904868
CUSIP
N/A
ISIN
DE000FRE5EN2
Created
07/12/2025, 04:06:36
Last update
22/09/2026, 13:03:39

Track Fresenius SE & Co. KGaA with an AI analyst

See which prediction-market events move FSNUF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to FSNUF from your Railway `news_articles` table.

No news found for this symbol.